PROAIR DIGIHALER
Clinical safety rating
cautionComprehensive clinical and safety monograph for PROAIR DIGIHALER (PROAIR DIGIHALER).
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, resulting in bronchodilation.
| Metabolism | Primarily metabolized by conjugation (sulfation) in the gastrointestinal tract and liver; minor CYP450 metabolism. |
| Excretion | Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2% |
| Half-life | Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation |
| Protein binding | Approximately 10% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | Vd of albuterol is approximately 1.0-4.0 L/kg (mean 2.5 L/kg), indicating extensive distribution into tissues |
| Bioavailability | Inhalation: mean absolute bioavailability from a metered-dose inhaler is approximately 7% of the administered dose, though systemic exposure varies with inhaler technique |
| Onset of Action | Inhalation: onset of bronchodilation occurs within 5-15 minutes |
| Duration of Action | Inhalation: duration of bronchodilation is 3-6 hours, with some effect lasting up to 6 hours as per product labeling |
| Molecular Weight | 239.31 |
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
| Dosage form | POWDER, METERED |
| Renal impairment | No dose adjustment required for renal impairment. Albuterol is primarily hepatically metabolized and renally excreted as metabolites; however, no specific GFR-based guidelines exist. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment due to potential accumulation; monitor for adverse effects. |
| Pediatric use | Children 4-11 years: 90-180 mcg (1-2 inhalations) every 4-6 hours as needed. For exercise-induced bronchospasm: 90-180 mcg 15 minutes before exercise. Weight-based dosing not typically used; follow age-based guidelines. |
| Geriatric use | No specific dose adjustment required. Use lowest effective dose due to potential increased sensitivity and comorbidities. Monitor for tachycardia, tremor, and hypertension. |
| 1st trimester | Albuterol is generally considered safe during the first trimester; however, limited human data exist. Avoid unnecessary use. No significant teratogenic risk reported. |
| 2nd trimester | Safe for use in second trimester when clinically indicated. Monitor maternal heart rate and glucose. |
| 3rd trimester | Use with caution in third trimester due to potential for maternal tachycardia, hyperglycemia, and possible inhibition of uterine contractions. Risk of fetal tachycardia. |
Clinical note
Comprehensive clinical and safety monograph for PROAIR DIGIHALER (PROAIR DIGIHALER).
| Placental transfer | Albuterol crosses the placenta. The degree of placental transfer is moderate, with fetal serum levels approximately 50-80% of maternal levels. |
| Breastfeeding | Albuterol is excreted into breast milk in small amounts (estimated 0.2-0.7% of maternal dose). It is unlikely to cause adverse effects in the infant. Use with caution, especially with high doses, and monitor infant for signs of beta-agonist stimulation (e.g., tachycardia). |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. In humans, inhaled beta-agonists are not associated with an increased risk of major congenital malformations. However, maternal asthma exacerbations pose significant risks to the fetus, including preterm birth and low birth weight. Therefore, the benefit of controlled asthma outweighs the theoretical risks. First trimester exposure is not linked to increased malformation rates. Second and third trimester use is considered safe, with no known fetal toxicity at standard doses. No specific teratogenic risk profile by trimester is established. |
| Fetal Monitoring | Monitor maternal respiratory status, peak expiratory flow, and asthma control symptoms. In pregnancy, assess fetal growth and well-being via ultrasound if asthma is poorly controlled or if exacerbations occur. No specific fetal monitoring required for albuterol therapy alone, but monitoring for maternal heart rate and serum potassium is recommended during high-dose or continuous use. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies with albuterol. In humans, there is no evidence that inhaled beta-agonists impair fertility. However, uncontrolled asthma may be associated with reduced fertility due to chronic hypoxia. Therefore, maintaining asthma control is recommended for reproductive health. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to albuterol or any component of the formulationSevere hypersensitivity to lactose (inhaler contains lactose)
| Precautions | Paradoxical bronchospasm with fatal outcomes; discontinue immediately if occurs, Life-threatening asthma exacerbations; need for increased use may indicate worsening asthma, Cardiovascular effects: increased heart rate, hypertension, arrhythmias; use with caution in patients with cardiovascular disorders, Hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients, Rare anaphylactic reactions, Do not exceed recommended dose; excessive use may lead to death |
| Food/Dietary | No specific food-drug interactions are known for albuterol. However, caffeine-containing foods and beverages (coffee, tea, cola, energy drinks) may potentiate the stimulant effects (e.g., tachycardia, tremor). Hypokalemia may be potentiated by concurrent use of potassium-depleting diuretics or prolonged use. Avoid high-sulfite foods if a sulfite sensitivity is present, as these may trigger bronchospasm in some asthmatics. |
| Clinical Pearls | PROAIR DIGIHALER contains albuterol sulfate, a short-acting beta-2 agonist (SABA). It is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB). The device is breath-activated, requiring a low inspiratory flow rate (approx. 20 L/min) for optimal dose delivery. Shake well before each use. Priming is not needed for new inhalers if used within 2 weeks; if not used for more than 2 weeks, prime by releasing 1 test spray into the air. Rinse mouth with water after each use to reduce risk of oropharyngeal candidiasis. Avoid concomitant use of non-selective beta-blockers (e.g., propranolol) as they may antagonize bronchodilatory effects. Monitor for paradoxical bronchospasm, tachycardia, and hypokalemia. Not for acute severe asthma exacerbation requiring intensive care; use a nebulized SABA or IV bronchodilator instead. |
| Patient Advice | Use exactly as prescribed; do not exceed recommended doses. · Shake the inhaler well before each use. · Exhale fully, place mouthpiece between lips, inhale deeply and forcefully to activate the dose; hold breath for 10 seconds, then exhale slowly. · Rinse mouth with water after each use to prevent mouth and throat irritation. · Do not use if the inhaler has been dropped or damaged; check dose counter regularly. · Seek emergency medical attention if breathing problems worsen despite using this medication. · Avoid foods or beverages that may trigger asthma symptoms, such as sulfites (e.g., dried fruits, wine). · Avoid caffeine (coffee, tea, soda) as it may increase side effects like nervousness and rapid heartbeat. · Stay hydrated but avoid large amounts of cold water immediately before or after use. |
Loading safety data…